Growth Momentum In Biologics To Continue: Kiran Mazumdar Shaw, Biocon
  • WebDesk BTVI
  • Jul 26 2019

Kiran Mazumdar Shaw, CMD of Biocon, shared the company’s earnings report for the first quarter of FY20. She said company’s consolidated revenue at group level has grown 25% to Rs 1,490 crore, net profit saw 86% growth. On business outlook, she says the company is set to spend Rs 600 crore on vizag bulk drug unit over 3 years and adds that significant part of biologics growth to come in Q2.